Abstract:Guomin Gu, 1 Bo Yu, 2 Hua Wan, 2 Suqiong Lu, 1 Xiaodan Zhu, 1 Yan Zhao, 1 Yujing Fuxi, 1 Chunling Liu 1 1 Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830011, People's Republic of China; 2 Department of Medicine, Beijing USCI Medical Laboratory, Beijing, 100195, People's Republic of China Correspondence: Chunling Liu, Department of Pulmonary Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, No. 789 Suzhou East Street, Urumqi, Xinjiang, 830011, People's Republic of China, +Tel/Fax +86-991-7819352, Email Purpose: Non-small cell lung cancer (NSCLC) is a malignant tumor with high mortality. The Kirsten rat sarcoma vial oncogene ( KRAS ) gene can affect patient prognosis. In this study, we aim to explore the impact of KRAS mutation status on the clinical prognosis of NSCLC immunotherapy. Patients and Methods: Collected tumor samples from the Affiliated Cancer Hospital of Xinjiang Medical University and 220 patients with stage III–IV NSCLC were included the study. All patients are on first- or second-line therapy and not on targeted therapy. Based on the molecular profiles and clinical features, we analysis of the effect of KRAS mutation on the treatment outcome of NSCLC. Results: In this study, the main mutant subtypes of KRAS were G12C, G12D, and G12V. In the KRAS mutation group, the highest mutation frequency other than KRAS was TP53, followed by STK11 and KMT2C. We found that among patients received immunotherapy, KRAS -mutant patients were more sensitive to immunotherapy, with an objective response rate (ORR) of 65% and a disease control rate (DCR) of 80%. Survival analysis found that patients with KRAS mutation had better prognosis with immunotherapy than the non- KRAS mutation patients by comparing the overall survival (OS) (median OS: 18.1 months vs 12.2 months, p=0.0032) and progression-free survival (PFS) (media PFS: 7.9 months vs 3.6 months, p=0.01). We found that the patients with KRAS mutation had better prognosis with immunotherapy than with chemotherapy (median OS: 18.1 months vs 12.3 months, p=0.039, PFS 7.9 months vs 4.1 months, p=0.001). Patients with the KRAS G12C mutation had better results with immunotherapy than chemotherapy, but there was no significant difference in outcome between the two groups (OS: p=0.26 PFS: p=0.055). KRAS and TP53 co-mutation and KRAS and KMT2C co-mutation may improve response to immunotherapy. Conclusion: Our results suggested that the gene mutation profile of NSCLC in KRAS mutation group and non- KRAS mutation group were different. The patients with KRAS mutation will have better prognosis with immunotherapy. Keywords: NSCLC, KRAS , mutation, immunotherapy, prognosis Non-small cell lung cancer (NSCLC), one of the major histological classes of lung cancer, is approximately 85% of all lung cancer. 1 With the tumor gene detection becoming the recommended method among national guidelines for the diagnosis and treatment of cancer patients, 2 Kirsten rat sarcoma vial oncogene ( KRAS ) gene has been shown to be one of the most prevalent oncogenic drivers of human cancer. 3 KRAS , along with NRAS , and HRAS genes, members of the Ras superfamily, is the first identified human oncogene in 1982. 4 Several meta-analyses have shown that the frequency of KRAS mutations is associated with regions, accounting for 26.1% of individual mutation rates in lung adenocarcinoma (LUAD) among Western and about 11.2% of Asian patients. 5 The human KRAS gene is located in chromosome 12.p12.1, and the most frequent mutations that occur in condon 12 in NSCLC are G12C, G12D, and G12V. Those common G12 mutations are commonly associated with poor prognosis. 6–8 For more than three decades, there have not been highly efficient promising drugs targeting KRAS mutations developed, untill sotorasib (AMG510) being approved by FDA for the treatment of patients with advanced KRAS G12C-mutant NSCLC following at least one prior systemic therapy in 2021. 9,10 However, chemotherapy is yet the standard treatment for advanced NSCLC patients with KRAS mutations. The development of immune checkpoint inhibitors (ICIs) immunotherapy should be a rising therapy in curing KRAS mutation patients. 11–14 A meta-analysis by Lee et al reported that ICIs appeared to improve survival compared to docetaxel, in the subgroup of KRAS mutant patients but not in KRAS</e -Abstract Truncated-

Characterization of Distinct Types of KRAS Mutation and Its Impact on First-Line Platinum-Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer

Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients Following First-Line Treatment.

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer.

The Prevalence and Prognostic Significance of KRAS Mutation Subtypes in Lung Adenocarcinomas from Chinese Populations

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.

Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China

P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations

Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

A Retrospective Observational Study of the Natural History of Advanced Non-Small-cell Lung Cancer in Patients with KRAS P.g12c Mutated or Wild-Type Disease.

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Kras Mutations And Resistance To Egfr-Tkis Treatment In Patients With Non-Small Cell Lung Cancer: A Meta-Analysis Of 22 Studies

The Relationship Between Different Subtypes of KRAS and PD-L1 & Tumor Mutation Burden (TMB) Based on Next-Generation Sequencing (NGS) Detection in Chinese Lung Cancer Patients